{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:14:00Z","timestamp":1782458040699,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prognostic biomarkers of treatment response to distinct biologic disease-modifying anti-rheumatic drugs (b-DMARDs) are still lacking within the management of rheumatoid arthritis (RA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-four b-DMARDs naive RA patients, divided by disease duration into early (cohort 1) and long standing (cohort 2), received CTLA4-Ig. At study entry, and every 3\u00a0months for 1\u00a0year, each patient underwent peripheral blood (PB)-derived CD4<jats:sup>pos<\/jats:sup> cell subpopulation assessment by flow cytometry, STAT3 and STAT5 expression by RT-PCR and IL-6, IL-12p70, TGF\u03b2, and IL-10 serum levels by ELISA. The DAS and CDAI remission was assessed at 6 and 12\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DAS- and CDAI-defined remission within 12\u00a0months was achieved by 16 (47.1%) and 8 (23.5%) RA\u00a0patients, respectively. Considering the whole RA cohort, CTLA4-Ig induced a significant decrease of IL-6 serum levels from baseline to 6 and 12\u00a0months, as well as of PB CD4<jats:sup>pos<\/jats:sup>CD25<jats:sup>pos<\/jats:sup>FoxP3<jats:sup>pos<\/jats:sup> cells at 6 and 12\u00a0months, and of CD4<jats:sup>pos<\/jats:sup>IL17<jats:sup>pos<\/jats:sup> cells after 12\u00a0months. PB CD4<jats:sup>pos<\/jats:sup> cells of RA patients showed higher STAT3 and STAT5 expression than healthy controls, which remained unchanged within 12\u00a0months of treatment. At study entry, RA patients achieving DAS remission had significantly lower IL-6 serum levels than RA patients not achieving this outcome. In particular, having baseline IL-6 serum levels\u2009\u2264\u20098.4\u00a0pg\/ml, significantly identified na\u00efve to b-DMARDs RA patients more likely to achieve DAS-remission under CTLA4-Ig at 6\u00a0months (66.7%) compared to RA patients with baseline IL-6 serum levels\u2009&gt;\u20098.4\u00a0pg\/ml [15.4%, OR (95%Cis) 11.00 (1.75\u201355.82)]. Moreover, having CD4<jats:sup>pos<\/jats:sup>CD25<jats:sup>pos<\/jats:sup>FoxP3<jats:sup>pos<\/jats:sup> cells rate\u2009\u2265\u20096.0% significantly identifies na\u00efve to b-DMARDs early RA patients more likely to achieve DAS remission at 6\u00a0months (83.3%) compared to RA patients with baseline CD4<jats:sup>pos<\/jats:sup>CD25<jats:sup>pos<\/jats:sup>FoxP3<jats:sup>pos<\/jats:sup> cells\u2009&lt;\u20096.0% [16.7%, OR (95% Cis) 25.00 (1.00\u2013336.81)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Baseline IL-6 serum levels and peripheral blood-derived CD4<jats:sup>pos<\/jats:sup> subpopulations are putative novel prognostic biomarkers of CTLA4-Ig response in RA patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02827-5","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:03:04Z","timestamp":1655272984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig"],"prefix":"10.1186","volume":"24","author":[{"given":"Elisa","family":"Gremese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tolusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Petricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Di Mario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Alivernini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"2827_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","volume":"79","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:744\u201359.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis. 2019;78:761\u201372.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/art.41726","volume":"73","author":"S Alivernini","year":"2021","unstructured":"Alivernini S, Tolusso B, Gessi M, Gigante MR, Mannocci A, Petricca L, et al. Inclusion of synovial tissue-derived characteristics in a nomogram for the prediction of treatment response in treatment-naive rheumatoid arthritis patients. Arthritis Rheumatol. 2021;73:1601\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"2827_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/rheumatology\/kex012","volume":"57","author":"S Nakayamada","year":"2018","unstructured":"Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, et al. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018;57:164\u201374.","journal-title":"Rheumatology (Oxford)"},{"key":"2827_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13075-018-1648-2","volume":"20","author":"J Aldridge","year":"2018","unstructured":"Aldridge J, Pandya JM, Meurs L, Andersson K, Nordstr\u00f6m I, Theander E, et al. Sex-based differences in association between circulating T cell subsets and disease activity in untreated early rheumatoid arthritis patients. Arthritis Res Ther. 2018;20:150.","journal-title":"Arthritis Res Ther"},{"key":"2827_CR6","volume":"2015","author":"A Alunno","year":"2015","unstructured":"Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E, et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm. 2015;2015: 751793.","journal-title":"Mediators Inflamm"},{"key":"2827_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/ard.2006.068320","volume":"66","author":"F Behrens","year":"2007","unstructured":"Behrens F, Himsel A, Rehart S, Stanczyk J, Beutel B, Zimmermann SY, et al. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1151\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR8","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1136\/ard.2008.100768","volume":"68","author":"S Raghavan","year":"2009","unstructured":"Raghavan S, Cao D, Widhe M, Roth K, Herrath J, Engstr\u00f6m M, et al. FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann Rheum Dis. 2009;68:1908\u201315.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/03009742.2012.696135","volume":"41","author":"E Xq","year":"2012","unstructured":"Xq E, Meng HX, Cao Y, Zhang SQ, Bi ZG, Yamakawa M. Distribution of regulatory T cells and interaction with dendritic cells in the synovium of rheumatoid arthritis. Scand J Rheumatol. 2012;41:413\u201320.","journal-title":"Scand J Rheumatol"},{"key":"2827_CR10","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar4545","volume":"16","author":"B Moradi","year":"2014","unstructured":"Moradi B, Schnatzer P, Hagmann S, Rosshirt N, Gotterbarm T, Kretzer JP, et al. CD4+CD25+\/highCD127low\/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints\u2013analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther. 2014;16:R97.","journal-title":"Arthritis Res Ther"},{"key":"2827_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cei.12017","volume":"171","author":"B Pesce","year":"2013","unstructured":"Pesce B, Soto L, Sabugo F, Wurmann P, Cuchacovich M, L\u00f3pez MN, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol. 2013;171:237\u201342.","journal-title":"Clin Exp Immunol"},{"key":"2827_CR12","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2827_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1746-1596-8-61","volume":"8","author":"Z Chen","year":"2013","unstructured":"Chen Z, Ding J, Pang N, Du R, Meng W, Zhu Y, et al. The Th17\/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol. 2013;8:61.","journal-title":"Diagn Pathol"},{"key":"2827_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jim.2012.09.014","volume":"387","author":"L Nettenstrom","year":"2013","unstructured":"Nettenstrom L, Alderson K, Raschke EE, Evans MD, Sondel PM, Olek S, et al. An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood. J Immunol Methods. 2013;387:81\u20138.","journal-title":"J Immunol Methods"},{"key":"2827_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ni846","volume":"3","author":"U Grohmann","year":"2002","unstructured":"Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3:1097\u2013101.","journal-title":"Nat Immunol"},{"key":"2827_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/ni1003","volume":"4","author":"F Fallarino","year":"2003","unstructured":"Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4:1206\u201312.","journal-title":"Nat Immunol"},{"key":"2827_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.12.007","volume":"87","author":"R Stadhouders","year":"2018","unstructured":"Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018;87:1\u201315.","journal-title":"J Autoimmun"},{"key":"2827_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2017.12.003","volume":"87","author":"T Agalioti","year":"2018","unstructured":"Agalioti T, Villablanca EJ, Huber S, Gagliani N. TH17 cell plasticity: the role of dendritic cells and molecular mechanisms. J Autoimmun. 2018;87:50\u201360.","journal-title":"J Autoimmun"},{"key":"2827_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2119\/molmed.2011.00034","volume":"17","author":"A Michelutti","year":"2011","unstructured":"Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tolusso B, et al. B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status. Mol Med. 2011;17:901\u20139.","journal-title":"Mol Med"},{"key":"2827_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/cei.13098","volume":"193","author":"S Alivernini","year":"2018","unstructured":"Alivernini S, Tolusso B, Ferraccioli G, Gremese E, Kurowska-Stolarska M, McInnes IB. Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clin Exp Immunol. 2018;193:13\u201323.","journal-title":"Clin Exp Immunol"},{"key":"2827_CR22","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1445::AID-IMMU1445>3.0.CO;2-M","volume":"30","author":"T Nguyen","year":"2000","unstructured":"Nguyen T, Wang R, Russell JH. IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur J Immunol. 2000;30:1445\u20135210.","journal-title":"Eur J Immunol"},{"key":"2827_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature01355","volume":"421","author":"DJ Cua","year":"2003","unstructured":"Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744\u2013810.","journal-title":"Nature"},{"key":"2827_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-014-0363-2","volume":"13","author":"L Imberti","year":"2015","unstructured":"Imberti L, Scarsi M, Zanotti C, Chiarini M, Bertoli D, Tincani A, et al. Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients. J Transl Med. 2015;13:12.","journal-title":"J Transl Med"},{"key":"2827_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/rheumatology\/kev403","volume":"55","author":"M Bonelli","year":"2016","unstructured":"Bonelli M, G\u00f6schl L, Bl\u00fcml S, Karonitsch T, Hirahara K, Ferner E, et al. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Rheumatology (Oxford). 2016;55:710\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"2827_CR26","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1007\/s10067-021-05602-0","volume":"40","author":"J Inamo","year":"2021","unstructured":"Inamo J, Kaneko Y, Kikuchi J, Takeuchi T. High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis. Clin Rheumatol. 2021;40:3615\u201326.","journal-title":"Clin Rheumatol"},{"key":"2827_CR27","doi-asserted-by":"publisher","first-page":"e0215192","DOI":"10.1371\/journal.pone.0215192","volume":"14","author":"S Maeda","year":"2019","unstructured":"Maeda S, Osaga S, Maeda T, Takeda N, Tamechika SY, Naniwa T, et al. Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: an exploratory research. PLoS One. 2019;14:e0215192.","journal-title":"PLoS One"},{"key":"2827_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.ai.2017.01.001","volume":"134","author":"A Kelly","year":"2017","unstructured":"Kelly A, Houston SA, Sherwood E, Casulli J, Travis MA. Regulation of innate and adaptive immunity by TGF\u03b2. Adv Immunol. 2017;134:137\u2013233.","journal-title":"Adv Immunol"},{"key":"2827_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molmed.2016.07.003","volume":"22","author":"IR Kasper","year":"2016","unstructured":"Kasper IR, Apostolidis SA, Sharabi A, Tsokos GC. Empowering regulatory T cells in autoimmunity. Trends Mol Med. 2016;22:784\u201397.","journal-title":"Trends Mol Med"},{"key":"2827_CR30","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1002\/art.34601","volume":"64","author":"JH Ju","year":"2012","unstructured":"Ju JH, Heo YJ, Cho ML, Jhun JY, Park JS, Lee SY, et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum. 2012;64:3543\u201352.","journal-title":"Arthritis Rheum"},{"key":"2827_CR31","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.autrev.2017.09.002","volume":"16","author":"S Alivernini","year":"2017","unstructured":"Alivernini S, Galeazzi M, Peleg H, Tolusso B, Gremese E, Ferraccioli G, et al. Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons Autoimmun Rev. 2017;16:1096\u2013102.","journal-title":"Pros and cons Autoimmun Rev"},{"key":"2827_CR32","doi-asserted-by":"crossref","unstructured":"Aldridge J, Andersson K, Gjertsson I, Ekwall AH, Hallstr\u00f6m M, van Vollenhoven R, et al. Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. Rheumatology (Oxford). 2022;61(3):1233\u201342.","DOI":"10.1093\/rheumatology\/keab454"},{"key":"2827_CR33","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1136\/bmj.m4328","volume":"371","author":"ML Hetland","year":"2020","unstructured":"Hetland ML, Haavardsholm EA, Rudin A, Nordstr\u00f6m D, Nurmohamed M, Gudbjornsson B, NORD-STAR study group, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:4328.","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1186\/s13075-022-02866-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000}}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02827-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02827-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02827-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T12:07:29Z","timestamp":1658750849000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02827-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2827"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02827-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13075-022-02866-y","URL":"https:\/\/doi.org\/10.1186\/s13075-022-02866-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by local ethic committee of the Universit\u00e0 Cattolica del Sacro Cuore.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each enrolled patient signed an informed consent before study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}